A Potential Link Between Aberrant Expression of ECRG4 and Atrial Fibrillation

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Mar 13

PMID 36910669

Authors

Zuojing Zhang

Wei Wang

Yuxin Zhang

Xingji You

Jingxiang Wu

Affiliations

Soon will be listed here.

Abstract

Esophageal cancer-related gene-4 (ECRG4), a 148-amino acid propertied and new tumor suppressor, is initially cloned from the normal esophageal epithelium. ECRG4 was found to be expressed not only in esophageal tissues but also in cardiomyocytes. Previous studies demonstrated that ECRG4 is constitutively expressed in esophageal epithelial cells, and its degree of downregulation is directly proportional to prognosis in patients with esophageal cancer. In the heart, ECRG4 shows greater expression in the atria than in the ventricles, which accounts for its heterogeneity. Downregulation of ECRG4 expression level correlates with esophageal cancer, as well as myocardial injuries and arrhythmias. As a result, this review summarizes the possible susceptibility gene, ECRG4 and its associated molecular mechanisms in cancer patients with atrial fibrillation and myocardial injury. The review begins by describing ECRG4's biological background, discusses its expression in the cardiovascular system, lists the clinical and animal research related to the downregulation of ECRG4 in atrial fibrillation, and focuses on its potential role in atrial fibrillation. Downregulation of ECRG4 may increase the risk of atrial fibrillation by affecting ion channels, MMPs expression and inflammatory response. We will then discuss how ECRG4 can be used in the treatment of tumors and arrhythmias, and provide a novel possible strategy to reduce the occurrence of perioperative cardiovascular adverse events in patients with tumors such as esophageal cancer and gastric cancer.

References

Zhou R, Liu Y, Huang W, Dang X . Potential functions of esophageal cancer-related gene-4 in the cardiovascular system. Front Med. 2019; 13(6):639-645. DOI: 10.1007/s11684-019-0701-0. View

Tamariz L, Hernandez F, Bush A, Palacio A, Hare J . Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2014; 11(7):1102-8. DOI: 10.1016/j.hrthm.2014.04.003. View

Warton K, Mahon K, Samimi G . Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr Relat Cancer. 2016; 23(3):R157-71. PMC: 4737995. DOI: 10.1530/ERC-15-0369. View

Baird A, Coimbra R, Dang X, Lopez N, Lee J, Krzyzaniak M . Cell surface localization and release of the candidate tumor suppressor Ecrg4 from polymorphonuclear cells and monocytes activate macrophages. J Leukoc Biol. 2012; 91(5):773-81. PMC: 3336773. DOI: 10.1189/jlb.1011503. View

Jia J, Dai S, Sun X, Sang Y, Xu Z, Zhang J . A preliminary study of the effect of ECRG4 overexpression on the proliferation and apoptosis of human laryngeal cancer cells and the underlying mechanisms. Mol Med Rep. 2015; 12(4):5058-64. PMC: 4581775. DOI: 10.3892/mmr.2015.4059. View

Blencowe N, Strong S, McNair A, Brookes S, Crosby T, Griffin S . Reporting of short-term clinical outcomes after esophagectomy: a systematic review. Ann Surg. 2012; 255(4):658-66. DOI: 10.1097/SLA.0b013e3182480a6a. View

Ostenfeld E, Erichsen R, Pedersen L, Farkas D, Weiss N, Sorensen H . Atrial fibrillation as a marker of occult cancer. PLoS One. 2014; 9(8):e102861. PMC: 4138009. DOI: 10.1371/journal.pone.0102861. View

Dorschner R, Lee J, Cohen O, Costantini T, Baird A, Eliceiri B . ECRG4 regulates neutrophil recruitment and CD44 expression during the inflammatory response to injury. Sci Adv. 2020; 6(11):eaay0518. PMC: 7065879. DOI: 10.1126/sciadv.aay0518. View

Wu Y, Xiang Q, Lv X, Xiang X, Feng Z, Tian S . C2orf40 inhibits hepatocellular carcinoma through interaction with UBR5. J Gastroenterol Hepatol. 2021; 36(9):2581-2591. DOI: 10.1111/jgh.15441. View

10.

Botto F, Srinathan S, Pearse R, Biccard B, Rodseth R, Sheth T . Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology. 2014; 120(3):564-78. DOI: 10.1097/ALN.0000000000000113. View

11.

Mesubi O, Anderson M . Atrial remodelling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal. Cardiovasc Res. 2016; 109(4):542-57. PMC: 4777912. DOI: 10.1093/cvr/cvw002. View

12.

Iwasaki Y, Nishida K, Kato T, Nattel S . Atrial fibrillation pathophysiology: implications for management. Circulation. 2011; 124(20):2264-74. DOI: 10.1161/CIRCULATIONAHA.111.019893. View

13.

Porzionato A, Rucinski M, Macchi V, Sarasin G, Malendowicz L, De Caro R . ECRG4 expression in normal rat tissues: expression study and literature review. Eur J Histochem. 2015; 59(2):2458. PMC: 4503965. DOI: 10.4081/ejh.2015.2458. View

14.

Kujuro Y, Suzuki N, Kondo T . Esophageal cancer-related gene 4 is a secreted inducer of cell senescence expressed by aged CNS precursor cells. Proc Natl Acad Sci U S A. 2010; 107(18):8259-64. PMC: 2889548. DOI: 10.1073/pnas.0911446107. View

15.

Jiang Z, Dai L, Song Z, Li H, Shu M . Association between C-reactive protein and atrial fibrillation recurrence after catheter ablation: a meta-analysis. Clin Cardiol. 2013; 36(9):548-54. PMC: 6649439. DOI: 10.1002/clc.22157. View

16.

Mirabeau O, Perlas E, Severini C, Audero E, Gascuel O, Possenti R . Identification of novel peptide hormones in the human proteome by hidden Markov model screening. Genome Res. 2007; 17(3):320-7. PMC: 1800923. DOI: 10.1101/gr.5755407. View

17.

Perman J, Bostrom P, Lindbom M, Lidberg U, Stahlman M, Hagg D . The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest. 2011; 121(7):2625-40. PMC: 3223818. DOI: 10.1172/JCI43068. View

18.

Kurabi A, Pak K, Dang X, Coimbra R, Eliceiri B, Ryan A . Ecrg4 attenuates the inflammatory proliferative response of mucosal epithelial cells to infection. PLoS One. 2013; 8(4):e61394. PMC: 3634077. DOI: 10.1371/journal.pone.0061394. View

19.

Li C, Zhang P, Jiang A, Mao J, Wei G . A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer. Oncotarget. 2017; 8(26):41963-41974. PMC: 5522041. DOI: 10.18632/oncotarget.16713. View

20.

Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou E . RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget. 2017; 8(13):21429-21443. PMC: 5400595. DOI: 10.18632/oncotarget.15249. View